Amer Zeidan, MBBS, discusses current treatment approaches for patients with lower-risk MDS and ongoing challenges with available therapies.
Back
Delving Into Key Updates in MDS From ASH 2025
Amer Zeidan, MBBS, reviews key updates in myelodysplastic syndromes (MDS) presented at the 2025 ASH Annual Meeting. The program highlights real-world and clinical trial data shaping care for patients with lower-risk MDS, including insights on treatment initiation and outcomes with luspatercept
Delving Into Key Updates in MDS From ASH 2025
Episodes
All
All
Amer Zeidan, MBBS, discusses factors that can influence the initiation of treatment in lower-risk MDS.
Amer Zeidan, MBBS, details data from ASH 2025 on real-world outcomes with luspatercept in lower-risk MDS.
Amer Zeidan, MBBS, unpacks data from a post hoc analysis of the COMMANDS trial of luspatercept in lower-risk MDS.
Amer Zeidan, MBBS, breaks down other key data in lower-risk MDS to emerge from ASH 2025.
Amer Zeidan, MBBS, spotlights ongoing research to watch in higher-risk MDS after ASH 2025.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5